Poly Medicure Limited — Investor Meet, 11-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Poly Medicure's Q3 FY26 consolidated revenue rose 16.4% YoY to INR 494 Cr. PAT was INR 71 Cr, impacted by one-time costs. 9M revenue grew 9.1% to INR 1,341 Cr, with standalone EBITDA at a robust 26.6%.

The company is strategically shifting to high-growth areas like cardiology, critical care, and orthopedics, bolstered by recent acquisitions. New products (Intravenous Lithotripsy System, Drug Eluting Balloon) are approved for India, tapping into import-heavy segments. Management anticipates 20%+ revenue growth for FY27, driven by domestic expansion and international market recovery with enhanced clinical engagement.